Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MyoCell II + stromal cell-derived factor 1
- Development stage
- Discontinued
- Lead developer
- Bioheart
- Modality
- Cell Therapies, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramyocardial
01
Overview
MyoCell II + stromal cell-derived factor 1 is an experimental combination therapy developed for cardiac regeneration, specifically targeting congestive heart failure and myocardial infarction. The product consists of autologous skeletal myoblasts (MyoCell) combined with stromal cell-derived factor 1 (SDF-1), also known as CXCL12, which is typically delivered via a plasmid gene therapy or as a recombinant protein. The skeletal myoblasts are intended to integrate into damaged myocardial tissue to improve contractile function and ventricular wall thickness. SDF-1 acts as a potent chemoattractant that binds to the CXCR4 receptor, facilitating the homing, retention, and survival of the transplanted myoblasts while simultaneously recruiting endogenous stem cells to the site of injury to promote angiogenesis and tissue repair. This dual-action approach aims to overcome the limitations of single-cell therapies by enhancing the microenvironment for cardiac recovery.
- Other names
- MyoCell SDF-1Autologous skeletal myoblasts + SDF-1MyoCell II + CXCL12
02
Targets
CXCR7 (CXC chemokine receptor 7)CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on MyoCell II + stromal cell-derived factor 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MyoCell II + stromal cell-derived factor 1.